BR0212880A - Uso de uma droga moduladora de lipìdeo, kit para tratamento ou redução, stent revestido com um material a ser liberado em um local a ser tratado, e composição farmacêutica - Google Patents
Uso de uma droga moduladora de lipìdeo, kit para tratamento ou redução, stent revestido com um material a ser liberado em um local a ser tratado, e composição farmacêuticaInfo
- Publication number
- BR0212880A BR0212880A BR0212880-2A BR0212880A BR0212880A BR 0212880 A BR0212880 A BR 0212880A BR 0212880 A BR0212880 A BR 0212880A BR 0212880 A BR0212880 A BR 0212880A
- Authority
- BR
- Brazil
- Prior art keywords
- apolipoprotein
- lipid
- treatment
- therapy
- apolipoproteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
"USO DE UMA DROGA MODULADORA DE LIPìDEO, KIT PARA TRATAMENTO OU REDUçãO, STENT REVESTIDO COM UM MATERIAL A SER LIBERADO EM UM LOCAL A SER TRATADO, E COMPOSIçãO FARMACêUTICA". A apolipoproteína A-I (ApoA-I), preferivelmente uma forma variante tal como Apolipoproteína A-1 Milano (ApoA-IM), sozinha ou mais preferivelmente em combinação com um veículo lipídico, tal como fosfolipídeos ou outro medicamento, pode ser administrada localmente antes ou durante cirurgia de desvio de artérias coronárias, periféricas e cerebrais adoentadas, cirurgia para implantar enxertos ou órgãos transplantados, ou angioplastia, ou para estabilizar placas instáveis. Em uma modalidade alternativa, a apolipoproteína não é provida diretamente, porém o gene codificando a apolipoproteína o é. O gene é introduzido dentro do vaso sang³íneo de uma maneira similar àquela usada para a proteína, onde a proteína é então expressa. A técnica pode também ser usada para suprimento de genes para tratamento ou prevenção da restenose ou outras doenças cardiovasculares. Em ainda outra modalidade, os 'stents' são revestidos com apenas apolipoproteínas, apolipoproteínas formuladas com lipídeos, células geneticamente construídas expressando as apolipoproteínas, DNA desnudo codificando para uma apolipoproteína, ou outros medicamentos, tais como antiproliferativos para suprimento local em um sítio ferido. Em uma modalidade preferida, o sistema é usado com terapia de combinação, com suprimento local de um agente tal como uma apolipoproteína, em combinação com terapia anti-hipertensão sistêmica, terapia antiinflamatória, terapia de regulação de lipídeos e/ou anti-coagulação. Estes tratamentos podem começar antes de, concomitantemente com ou em seguida a suprimento local.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32637901P | 2001-09-28 | 2001-09-28 | |
PCT/US2002/031068 WO2003026492A2 (en) | 2001-09-28 | 2002-09-27 | Prevention and treatment of restenosis by local administration of drug |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0212880A true BR0212880A (pt) | 2005-12-13 |
Family
ID=23271954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0212880-2A BR0212880A (pt) | 2001-09-28 | 2002-09-27 | Uso de uma droga moduladora de lipìdeo, kit para tratamento ou redução, stent revestido com um material a ser liberado em um local a ser tratado, e composição farmacêutica |
Country Status (15)
Country | Link |
---|---|
US (1) | US8119590B2 (pt) |
EP (1) | EP1438060B1 (pt) |
JP (1) | JP2005504085A (pt) |
KR (1) | KR20040081418A (pt) |
CN (2) | CN1943790A (pt) |
AU (1) | AU2002362612B2 (pt) |
BR (1) | BR0212880A (pt) |
CA (1) | CA2460787A1 (pt) |
HK (1) | HK1075832A1 (pt) |
IL (1) | IL161110A0 (pt) |
MX (1) | MXPA04002848A (pt) |
NZ (1) | NZ532217A (pt) |
PL (1) | PL372925A1 (pt) |
WO (1) | WO2003026492A2 (pt) |
ZA (1) | ZA200402548B (pt) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7351421B2 (en) * | 1996-11-05 | 2008-04-01 | Hsing-Wen Sung | Drug-eluting stent having collagen drug carrier chemically treated with genipin |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
KR20040081418A (ko) | 2001-09-28 | 2004-09-21 | 에스페리온 테라피유틱스 인코포레이티드 | 약물의 국소투여를 통한 재협착의 예방 및 치료 |
WO2004037295A1 (en) * | 2002-10-22 | 2004-05-06 | Medtronic Ave, Inc. | Method and agent for treating vulnerable plaque |
US7641643B2 (en) * | 2003-04-15 | 2010-01-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
AP2006003578A0 (en) * | 2003-10-20 | 2006-04-30 | Esperion Therapeutics Inc | Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes. |
PE20050438A1 (es) * | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
WO2005046797A2 (en) * | 2003-11-05 | 2005-05-26 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
JP2007517550A (ja) * | 2004-01-02 | 2007-07-05 | アドヴァンスド カーディオヴァスキュラー システムズ, インコーポレイテッド | 高比重リポ蛋白をコーティングした医療デバイス |
US20050228473A1 (en) * | 2004-04-05 | 2005-10-13 | David Brown | Device and method for delivering a treatment to an artery |
US8926958B2 (en) | 2004-04-06 | 2015-01-06 | Cedars-Sinai Medical Center | Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano |
KR20060015963A (ko) * | 2004-08-16 | 2006-02-21 | 주식회사 스텐텍 | 셀레콕십을 포함하는 동맥 재협착 예방 및 치료를 위한 약학 조성물 |
US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
US9539410B2 (en) | 2005-04-19 | 2017-01-10 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating post-cardial infarction damage |
US20080125745A1 (en) | 2005-04-19 | 2008-05-29 | Shubhayu Basu | Methods and compositions for treating post-cardial infarction damage |
MX2007013430A (es) | 2005-04-29 | 2008-03-19 | Univ California | Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria. |
US20070254832A1 (en) * | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
US8785382B2 (en) | 2006-04-03 | 2014-07-22 | Abbott Cardiovascular Systems Inc. | Lipid therapy |
JP5394236B2 (ja) * | 2006-06-01 | 2014-01-22 | インスティトュート デ カーディオロジー デ モントリオール | 弁膜症治療方法及び化合物 |
EP2049137A4 (en) | 2006-08-08 | 2013-05-01 | Univ California | SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES |
US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
US20090036875A1 (en) * | 2007-07-30 | 2009-02-05 | Robert Glenmore Walsh | Cardiac tissue therapy |
US20090036965A1 (en) * | 2007-07-30 | 2009-02-05 | Robert Glenmore Walsh | Conjunctive stent therapy |
CN101361980B (zh) * | 2007-08-07 | 2011-07-20 | 山东省生物药物研究院 | 一种适合非注射途径给药的肝素磷脂复合物及其制备方法 |
JP2010538005A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法 |
WO2009032702A2 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
US8101565B2 (en) * | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
US8044021B2 (en) | 2007-09-20 | 2011-10-25 | Abbott Cardiovascular Systems Inc. | Sustained release of apo A-I mimetic peptides and methods of treatment |
US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
US9173890B2 (en) | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
US20090226501A1 (en) * | 2007-12-07 | 2009-09-10 | Boston Scientific Scimed, Inc. | Drug coated stent with endosome-disrupting conjugate |
US20090297577A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Local Delivery of Apolipoproteins and Their Derivatives |
WO2009152493A2 (en) * | 2008-06-13 | 2009-12-17 | The General Hospital Corporation | Use of apolipoproteins to decrease inflammation |
LT2939683T (lt) | 2009-02-16 | 2017-03-27 | Cerenis Therapeutics Holding Sa | Apolipoproteino a-i mimetikai |
ES2552654T3 (es) * | 2009-06-12 | 2015-12-01 | Medimmune, Llc | Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos |
CN102470196A (zh) * | 2009-08-27 | 2012-05-23 | 泰尔茂株式会社 | 药物输送用医疗器具 |
CN101716382B (zh) * | 2009-12-02 | 2015-07-15 | 浙江大学 | 一种质粒dna/纤维蛋白凝胶/聚合物三元复合支架的制备方法 |
MX2012014928A (es) | 2010-06-30 | 2013-03-22 | Csl Ltd | Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. |
WO2012024309A2 (en) | 2010-08-18 | 2012-02-23 | Cedars-Sinai Medical Center | Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer |
KR101255337B1 (ko) * | 2010-10-04 | 2013-04-16 | 한국과학기술연구원 | 온도 감응성 합성 고분자를 이용한 일산화질소 전달체 |
CN102240405A (zh) * | 2011-05-09 | 2011-11-16 | 上海市第十人民医院 | ApoA-Ⅰmilano基因药物 |
WO2012166798A2 (en) * | 2011-06-01 | 2012-12-06 | Wake Forest University Health Sciences | Systems and apparatus for indicating risk of coronary stenosis |
AU2012310259C1 (en) * | 2011-12-21 | 2016-07-14 | Csl Limited | Dosage regime for apolipoprotein formulations |
WO2014011908A1 (en) * | 2012-07-11 | 2014-01-16 | Esperion Therapeutics, Inc. | Apolipoprotein mixtures |
US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
CN103880949B (zh) * | 2014-03-05 | 2016-09-14 | 王家祥 | 类载脂蛋白c-i及其在制备治疗肾母细胞瘤的药物中的应用 |
US20150316566A1 (en) | 2014-05-02 | 2015-11-05 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
JP7081923B2 (ja) | 2014-07-31 | 2022-06-07 | ユーエイビー リサーチ ファンデーション | アポe模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果 |
WO2016044177A1 (en) * | 2014-09-17 | 2016-03-24 | The Regents Of The University Of California | Peptides having reduced toxicity that stimulate cholesterol efflux |
IL268093B1 (en) | 2017-01-19 | 2024-03-01 | Us Health | APOC-II mimic peptides |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2302698A (en) * | 1941-05-12 | 1942-11-24 | Albert M Kessel | Multiple tissue carrier |
US4009777A (en) * | 1975-12-29 | 1977-03-01 | Ryder International Corporation | Contact lens holder |
US4205747A (en) * | 1978-09-05 | 1980-06-03 | Cilco, Inc. | Lens storage device |
US4277172A (en) * | 1979-11-05 | 1981-07-07 | American Optical Corporation | Soft contact lens apparatus |
US4257521A (en) * | 1979-11-16 | 1981-03-24 | Stanley Poler | Packaging means for an intraocular lens |
US4326306A (en) * | 1980-12-16 | 1982-04-27 | Lynell Medical Technology, Inc. | Intraocular lens and manipulating tool therefor |
US4423809A (en) * | 1982-02-05 | 1984-01-03 | Staar Surgical Company, Inc. | Packaging system for intraocular lens structures |
US4439319A (en) * | 1982-07-16 | 1984-03-27 | Rock John G | Receptacle for the collection of medical specimens and the like |
US4970144A (en) * | 1984-12-31 | 1990-11-13 | International Genetic Engineering | Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use |
ATE68013T1 (de) * | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
GB2189596B (en) * | 1986-04-16 | 1990-08-01 | Pa Consulting Services | Methods of and apparatus for preparing tissue specimens |
US5019084A (en) * | 1986-08-06 | 1991-05-28 | Minnesota Mining And Manufacturing Company | Corneal holder |
US4697697A (en) * | 1986-08-18 | 1987-10-06 | Coopervision, Inc. | Method and apparatus for packaging an intraocular lens |
GB8625435D0 (en) | 1986-10-23 | 1986-11-26 | Erba Farmitalia | Human apolipoprotein ai |
US4750610A (en) * | 1986-12-29 | 1988-06-14 | Ryder International Corporation | Lens case with pressure sensitive venting system |
US4844242A (en) * | 1987-09-02 | 1989-07-04 | The Johns Hopkins University | Cornea retainer |
JP2917998B2 (ja) | 1988-02-05 | 1999-07-12 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | 修飾された肝細胞およびその用途 |
US5972890A (en) * | 1988-05-02 | 1999-10-26 | New England Deaconess Hospital Corporation | Synthetic peptides for arterial imaging |
CA1339354C (en) | 1988-09-01 | 1997-08-26 | The Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
IT1229996B (it) * | 1989-04-20 | 1991-09-20 | Cesare Sirtori | Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine. |
SE468881B (sv) | 1991-01-09 | 1993-04-05 | Kabi Pharmacia Ab | Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar |
SE9103701D0 (sv) * | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
WO1993018067A1 (en) | 1992-03-06 | 1993-09-16 | Abbott Laboratories | Immunocapture assay for direct quantitation of specific lipoprotein cholesterol levels |
WO1994000592A1 (en) | 1992-06-26 | 1994-01-06 | Exocell, Inc. | Monoclonal antibodies against glycated low density lipoprotein |
EP0671926B1 (en) * | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
US5424040A (en) * | 1992-11-09 | 1995-06-13 | Bjornsson; Bjorn L. | Tissue specimen collection kit |
US5281227A (en) * | 1992-11-09 | 1994-01-25 | Allergan, Inc. | Lens case with IOL folding device |
SE9203753D0 (sv) * | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
US5409833A (en) * | 1993-07-01 | 1995-04-25 | Baxter International Inc. | Microvessel cell isolation apparatus |
US6773719B2 (en) * | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
WO1995023592A1 (en) | 1994-03-04 | 1995-09-08 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
US5643757A (en) * | 1994-03-21 | 1997-07-01 | American Cyanamid Company | High yield production of human apolipoprotein A1 in E. coli. |
US5532168A (en) * | 1994-08-18 | 1996-07-02 | Marantz; Calvin | Tissue biopsy specimen strainer and method |
US5518612A (en) * | 1994-08-30 | 1996-05-21 | Becton, Dickinson And Company | Cell strainer assembly and method of use |
JP3691533B2 (ja) * | 1994-12-07 | 2005-09-07 | 財団法人化学及血清療法研究所 | 抗動脈硬化ペプチド |
SE9500778D0 (sv) * | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
US5609827A (en) * | 1995-05-02 | 1997-03-11 | Beekley Corporation | Biopsy specimen container |
US6258596B1 (en) * | 1995-05-22 | 2001-07-10 | Aventis Pharmaceuticals Products Inc. | Variants of apolipoprotein A-I |
FR2734568B1 (fr) | 1995-05-22 | 1997-06-20 | Rhone Poulenc Rorer Sa | Nouveaux variants de l'apolipoproteine |
US6074614A (en) * | 1995-06-07 | 2000-06-13 | Molecular Devices Corporation | Multi-assay plate cover for elimination of meniscus |
US5928935A (en) * | 1995-09-26 | 1999-07-27 | Reuss, Jr.; William Alexander | Biological specimen containment and incubation device |
EP0863748A4 (en) * | 1995-10-11 | 1999-11-03 | Kevin Jon William | LIPOSOMAL COMPOSITIONS AND METHODS OF USE |
KR0185334B1 (ko) * | 1995-11-02 | 1999-04-01 | 김은영 | 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이 |
GB9609702D0 (en) | 1996-05-09 | 1996-07-10 | Royal Free Hosp School Med | Anticoagulant peptides |
US5817032A (en) * | 1996-05-14 | 1998-10-06 | Biopath Automation Llc. | Means and method for harvesting and handling tissue samples for biopsy analysis |
JPH1025248A (ja) * | 1996-07-08 | 1998-01-27 | Chemo Sero Therapeut Res Inst | 抗血管リモデリング剤 |
SE9603068D0 (sv) * | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
SE9603304D0 (sv) * | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a compound |
SE9603303D0 (sv) * | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a protein |
GB9620153D0 (en) | 1996-09-27 | 1996-11-13 | Univ Strathclyde | Non-naturally occurring lipoprotein particle |
US7351421B2 (en) * | 1996-11-05 | 2008-04-01 | Hsing-Wen Sung | Drug-eluting stent having collagen drug carrier chemically treated with genipin |
GB9705831D0 (en) | 1997-03-20 | 1997-05-07 | Univ Leicester | Oxidised ldl |
US6635623B1 (en) | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
US6727102B1 (en) * | 1997-06-20 | 2004-04-27 | Leuven Research & Development Vzw | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins |
US6225070B1 (en) | 1997-08-07 | 2001-05-01 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma |
US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6156315A (en) | 1997-10-10 | 2000-12-05 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting the binding of low density lipoprotein to blood vessel matrix |
US6309844B1 (en) | 1997-10-15 | 2001-10-30 | Fujirebio Inc. | Anti-apo-B-48 monoclonal antibody, hybridoma producing the same, and method for measuring apo-B-48 using the same |
CA2323056A1 (en) | 1998-03-10 | 1999-09-16 | Regents Of The University Of California | Methods and tools for identifying compounds which modulate atherosclerosis by impacting ldl-proteoglycan binding |
WO2000002920A1 (en) | 1998-07-13 | 2000-01-20 | University Of Otago | Inhibition of lipoprotein formation |
JP2002541129A (ja) * | 1999-04-01 | 2002-12-03 | エスペリオン セラピューティクス インコーポレイテッド | エーテル化合物、組成物、およびそれらの使用 |
US6364098B2 (en) * | 1999-04-09 | 2002-04-02 | Third Millenium Trust | Soft contact lens cleaning and storage system |
DE60045869D1 (de) | 1999-10-26 | 2011-06-01 | Univ California | Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten |
AU2001233114A1 (en) | 2000-02-04 | 2001-08-14 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
MXPA02008616A (es) | 2000-03-03 | 2003-02-24 | Smithkline Beecham Biolog | Vacuna para el tratamiento de la arterosclerosis. |
SE0000855D0 (sv) | 2000-03-15 | 2000-03-15 | Karolinska Innovations Ab | Antigenic composition useful as a vaccine against atherosclerosis |
GB0017641D0 (en) | 2000-07-18 | 2000-09-06 | Medigene Oy | Peptides and their use |
EP1186299A1 (en) | 2000-09-12 | 2002-03-13 | Universitair Medisch Centrum Utrecht | The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system |
US7208288B2 (en) | 2000-10-13 | 2007-04-24 | Broderick Joseph P | Methods for enhancing the lysis of coagulated blood with apolipoprotein E2 phenotype |
WO2002048388A2 (en) | 2000-10-25 | 2002-06-20 | Vincent Agnello | Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell |
WO2002042426A2 (en) | 2000-11-10 | 2002-05-30 | University Of Utah Research Foundation | Carrier system for specific artery wall gene delivery |
EP2343317A1 (en) * | 2000-11-10 | 2011-07-13 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
SE0103754L (sv) | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
JP3944083B2 (ja) | 2001-05-15 | 2007-07-11 | 株式会社Jimro | 高密度リポ蛋白質反応性ペプチド |
EP1469887A4 (en) | 2001-07-20 | 2006-01-11 | Eidgenoess Tech Hochschule | COMPOSITIONS AND METHODS FOR USE AS BIOACTIVE AGENTS OF SULFATED AND SULFONATED AMINO ACIDS |
KR20040081418A (ko) | 2001-09-28 | 2004-09-21 | 에스페리온 테라피유틱스 인코포레이티드 | 약물의 국소투여를 통한 재협착의 예방 및 치료 |
PE20050438A1 (es) * | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
US8926958B2 (en) | 2004-04-06 | 2015-01-06 | Cedars-Sinai Medical Center | Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano |
-
2002
- 2002-09-27 KR KR10-2004-7004633A patent/KR20040081418A/ko not_active Application Discontinuation
- 2002-09-27 MX MXPA04002848A patent/MXPA04002848A/es active IP Right Grant
- 2002-09-27 CN CNA2006101537917A patent/CN1943790A/zh active Pending
- 2002-09-27 PL PL02372925A patent/PL372925A1/xx not_active Application Discontinuation
- 2002-09-27 BR BR0212880-2A patent/BR0212880A/pt not_active IP Right Cessation
- 2002-09-27 WO PCT/US2002/031068 patent/WO2003026492A2/en active Application Filing
- 2002-09-27 US US10/260,094 patent/US8119590B2/en not_active Expired - Fee Related
- 2002-09-27 CA CA002460787A patent/CA2460787A1/en not_active Abandoned
- 2002-09-27 IL IL16111002A patent/IL161110A0/xx unknown
- 2002-09-27 EP EP02799686.7A patent/EP1438060B1/en not_active Expired - Lifetime
- 2002-09-27 NZ NZ532217A patent/NZ532217A/en unknown
- 2002-09-27 AU AU2002362612A patent/AU2002362612B2/en not_active Ceased
- 2002-09-27 JP JP2003530138A patent/JP2005504085A/ja active Pending
- 2002-09-27 CN CNB028237811A patent/CN1283313C/zh not_active Expired - Fee Related
-
2004
- 2004-03-31 ZA ZA200402548A patent/ZA200402548B/en unknown
-
2005
- 2005-09-09 HK HK05107947A patent/HK1075832A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MXPA04002848A (es) | 2005-06-06 |
WO2003026492A3 (en) | 2003-10-16 |
KR20040081418A (ko) | 2004-09-21 |
NZ532217A (en) | 2006-12-22 |
JP2005504085A (ja) | 2005-02-10 |
WO2003026492A2 (en) | 2003-04-03 |
PL372925A1 (en) | 2005-08-08 |
US8119590B2 (en) | 2012-02-21 |
US20030109442A1 (en) | 2003-06-12 |
AU2002362612B2 (en) | 2007-11-15 |
EP1438060B1 (en) | 2015-11-11 |
CN1283313C (zh) | 2006-11-08 |
EP1438060A2 (en) | 2004-07-21 |
EP1438060A4 (en) | 2005-09-14 |
IL161110A0 (en) | 2004-08-31 |
CN1943790A (zh) | 2007-04-11 |
CN1596121A (zh) | 2005-03-16 |
HK1075832A1 (en) | 2005-12-30 |
ZA200402548B (en) | 2005-05-03 |
CA2460787A1 (en) | 2003-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0212880A (pt) | Uso de uma droga moduladora de lipìdeo, kit para tratamento ou redução, stent revestido com um material a ser liberado em um local a ser tratado, e composição farmacêutica | |
Barbato et al. | Nitric oxide and arterial disease | |
US7226589B2 (en) | Treatment of diseases by site specific instillation of cells or site specific transformation of cells and kits therefor | |
US5914345A (en) | Treatment of tissues to reduce subsequent response to injury | |
JP2005504085A5 (pt) | ||
ATE263553T1 (de) | Verabreichung von resveratrol zur vorbeugung oder behandlung von restenose nach coronarer eingriffe | |
ES2301602T3 (es) | Uso de un adn o arn para la fabricacion de un medicamento para el tratamiento de celulas tumorales. | |
Bartoli et al. | Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm | |
BR9808109A (pt) | Inibidor terapêutico de células vasculares da musculatura lisa | |
JP2006206611A (ja) | 微小管安定化剤を用いたアテローム性動脈硬化症または再狭窄症の治療方法 | |
AU2005251814A1 (en) | Local delivery of growth factors for stem cell transplantation | |
RU2005118750A (ru) | Органические соединения | |
Tominaga et al. | Effects of stent design and serum cholesterol level on the restenosis rate in atherosclerotic rabbits | |
JPH06509329A (ja) | 細胞の部位特異的な点滴注入または細胞の部位特異的形質転換による疾患の治療およびそのためのキット | |
HUP0002012A2 (hu) | Dezferriexochelin alkalmazása ateroszklerózis és érfalkárosodás kezelésére szolgáló gyógyszerkészítmények előállítására | |
Poyen et al. | Indications of coronary angioplasty and stenting in 2003: what is left to surgery? | |
WO1998042327B1 (en) | Vascular remodeling agent | |
Santoian et al. | Use of the porous balloon in porcine coronary arteries: rationale for low pressure and volume delivery | |
Badimon et al. | Vessel wall-related risk factors in acute vascular events | |
US20020034505A1 (en) | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor | |
You et al. | ε-Poly-l-lysine-hydroxyphenyl propionic acid/IL-4 composite hydrogels with inflammation regulation and antibacterial activity for improving integration stability of soft tissues and orthopedic implants | |
Kunwar et al. | A high risk unstable case of left main bifurcation lesion treated with simultaneous kissing stents as salvage procedure | |
EP2205226B1 (en) | Device for administering cells | |
Leonetti et al. | Effect of verapamil on atherosclerosis | |
KR20040008013A (ko) | 클로트리마졸을 포함하는 혈관 재협착 예방 및 치료용약학 조성물, 및 스텐트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE A 8.6 DA RPI 2108 DE 31/05/2011. |